Du är här

2016-01-21

Ablynx: ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION

GHENT, Belgium, 21 January 2016
-Ablynx[Euronext Brussels: ABLX; OTC: ABYLY]

today announced, in conformity with Title II of the Law of 2 May 2007 and the
Royal Decree of 14 February 2008, that an additional 288,170 common shares
have been issued by the Company in exchange for €1,192,292.70 as the result
of the exercise of warrants.

As a result of this transaction, Ablynx now has 55,100,544 shares outstanding.

The total number of rights (warrants) to subscribe to not yet issued
securities conferring voting rights currently is 2,528,657 which equals the
total number of voting rights that may result from the exercise of these
warrants. Currently 1,000 convertible bonds are outstanding entitling the
holders thereof to 7,733,952 shares of the Company in the aggregate, upon
conversion of such convertible bonds.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development ofNanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company
has approximately40 proprietary and partnered programmesin development in
various therapeutic areas including inflammation, haematology,
immuno-oncology, oncology and respiratory disease. The Company has
collaborations with multiple pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Eddingpharm, Genzyme, Merck&Co., Inc., Merck KGaA,
Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is
headquartered in Ghent, Belgium. More information can be found
onwww.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations
Instinctif Partners:

Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e:ablynx@instinctif.com

Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e:ablynx@instinctif.com

Pdf version of the press release
http://hugin.info/137912/R/1980185/725377.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1980185

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.